NCT02465515: A reported trial by GlaxoSmithKline
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02465515 |
|---|---|
| Title | A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 1, 2015 |
| Completion date | Feb. 20, 2018 |
| Required reporting date | Feb. 20, 2019, midnight |
| Actual reporting date | Feb. 11, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 23, 2025 |
| Days late | None |